Cagrilintide 5mg + Semaglutide 5mg – 10 Vials

Cagrilintide + Semaglutide Blend (also known as CagriSema in clinical contexts) is a research peptide combination comprising semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, and cagrilintide, a long-acting amylin analog. Semaglutide mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central and peripheral mechanisms. Cagrilintide activates amylin and calcitonin receptors to further promote satiety, delay gastric emptying through brainstem pathways, and complement GLP-1 signaling for synergistic effects on energy intake and homeostasis. In preclinical and phase 3 clinical models (e.g., REDEFINE trials), this dual-agonist blend achieves superior weight reduction—often 20-23% mean body weight loss over 68 weeks—compared to either monotherapy, alongside improved glycemic control (e.g., HbA1c reductions, normoglycemia in prediabetic subjects), cardiometabolic benefits (e.g., lowered blood pressure, lipids, inflammation), and enhanced satiety without proportional increases in adverse events beyond typical GLP-1-related gastrointestinal effects. The combination is utilized in research to investigate multi-hormonal approaches to obesity, type 2 diabetes, metabolic syndrome, appetite regulation pathways, and the therapeutic potential of amylin-GLP-1 synergy in overcoming compensatory mechanisms in energy balance and long-term weight management